Treatment
Risankizumab clinical trials
We’re tracking 21 recruiting studies that include Risankizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT06606808RecruitingPhase 1/Phase 2
Imaging risankizumab in inflammatory bowel disease
This trial tests a new imaging method using a special dye (risankizumab-800CW) to see how risankizumab, a medicine for inflammatory bowel disease, works in the bowel. The goal is to better understand the medicine's effects and help doctors tailor treatments.
GroningenAges 18 years+ - NCT04846959Recruiting
Pregnancy outcomes study for people exposed to risankizumab
This study looks at pregnancy outcomes in people who took risankizumab during pregnancy (or shortly before getting pregnant). It compares them with pregnancies exposed to similar biologic medicines, to better understand risks and what to expect.
Morrisville, North CarolinaAges Any age - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Dothan, AlabamaAges 18 years+ - NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Phoenix, ArizonaAges 2–17 - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT06298188Recruiting
Studying risankizumab in children with Crohn's disease
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
JerusalemAges 6–18 - NCT07466550RecruitingPhase 1
Study of how risankizumab moves through the body in healthy adults
This trial studies how the drug risankizumab moves through your body after being given through a vein or under the skin. It helps doctors understand the best way to give the medicine to patients.
Anaheim, CaliforniaAges 18–65 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07136116Recruiting
Study of risankizumab for moderate to severe ulcerative colitis in Japan
This study looks at how well risankizumab (an injected medicine) works for people with moderate to severe ulcerative colitis. It tracks your symptoms using a mobile app to see if the drug helps control the disease.
Nagakute, Aichi-kenAges 15 years+ - NCT06641089RecruitingPhase 3
Sonelokimab for psoriatic arthritis after TNF inhibitor failure
This study tests an investigational drug called sonelokimab for people with active psoriatic arthritis who have already tried a TNF-alpha inhibitor (like adalimumab) and it didn't work well enough. The goal is to see if sonelokimab can reduce joint pain and swelling and improve skin symptoms.
Avondale, ArizonaAges 18 years+ - NCT07039110Recruiting
Risankizumab for psoriasis: quality of life study
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
Calgary, AlbertaAges 18 years+ - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06548542RecruitingPhase 2
Targeted therapy study for moderate to severe Crohn's disease
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Dothan, AlabamaAges 18–75 - NCT06764693Recruiting
Study on treatment with Risankizumab for psoriatic arthritis
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
Quilmes, Buenos AiresAges 18–75 - NCT06764706Recruiting
Risankizumab for moderate-to-severe ulcerative colitis
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06865105RecruitingPhase 2
Targeted treatments for active psoriatic arthritis
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
Huntington Beach, CaliforniaAges 18 years+ - NCT07073079Recruiting
Study of upadacitinib and risankizumab for Crohn's after first therapy
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
Castellana Grotte, BariAges 18 years+ - NCT07166315Recruiting
Comparing new treatments for arthritis of the spine or joints
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Bath, SomersetAges 18 years+ - NCT07258745RecruitingPhase 1
Comparing a risankizumab biosimilar to Skyrizi in healthy adults
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
Warsaw, WarszawaAges 18–55
What Risankizumab is being studied for
Conditions with recruiting Risankizumab studies.
Common questions
- Are there clinical trials studying Risankizumab?
- Yes. Clin2 currently lists 21 recruiting studies that include Risankizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Risankizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Risankizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Risankizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.